Investor Relations

Print   Email  
Stock price graph
     

Ocera is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's lead program, OCR-002, is an ammonia scavenger designed to treat hyperammonemia (elevated ammonia in the blood) and associated hepatic encephalopathy, a complication of patients with liver cirrhosis.

View all »   RSSRecent Releases

Sep 29, 2014
Ocera Therapeutics to Present at 13th Annual BIO Investor Forum

Sep 18, 2014
Ocera Therapeutics Announces Appointment of Steven P. James to Board

Investors